FairJourney Biologics antibody research platform
Retained minority investment; exact current percentage not supplied
Ownership evidence checked ·
Partners Group's majority investment completed in 2024. GHO Capital reinvested a minority and founder António Parada retained a significant interest. The exact current split is not supplied. Iontas is the UK laboratory business; customer logos, including pharmaceutical groups, do not establish owned brands.
Ownership & related brands
Evidence · 4 sources
- FairJourney current investment case study (opens in a new tab)
Partners Group · Majority client investment and retained founder interest
Accessed 10 Oct 2026 - FairJourney majority sale and GHO reinvestment (opens in a new tab)
GHO Capital · 1 July 2024: majority sale agreement, GHO minority reinvestment and Iontas
Accessed 10 Oct 2026 - FairJourney current company identity (opens in a new tab)
FairJourney Bio · Completed 2024 investment; Cambridge / Iontas history
Accessed 10 Oct 2026 - GHO responsible-investing report 2024 (opens in a new tab)
GHO Capital · FairJourney case study: majority sale in September 2024
Accessed 10 Oct 2026